Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2021

Open Access 01-08-2021 | Post-Exposure Prophylaxis | Original Paper

Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP

Authors: Mart van Dijk, John B. F. de Wit, Thomas E. Guadamuz, Joel E. Martinez, Kai J. Jonas

Published in: AIDS and Behavior | Issue 8/2021

Login to get access

Abstract

Despite the improved availability and affordability of PrEP in the Netherlands, PrEP uptake is low among men who have sex with men (MSM). To optimize uptake, it is important to identify facilitators and barriers of PrEP use. During our study period, the price of PrEP dropped significantly after generic PrEP was introduced. We investigated whether the price drop predicts PrEP uptake, alongside behavioral and demographic characteristics. Participants (N = 349) were recruited online and completed three questionnaires over a period of 6 months, between February 2017 and March 2019. After 6 months, 159 (45.6%) participants were using PrEP. PrEP uptake was greater among MSM who ever had postexposure prophylaxis (PEP) treatment, among MSM with a better perceived financial situation, and when the price of PrEP dropped. MSM in a tighter perceived financial situation may use PrEP more when it would be free or fully reimbursed.
Appendix
Available only for authorised users
Literature
1.
Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.PubMedCrossRef
2.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef
3.
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.PubMedPubMedCentralCrossRef
4.
Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.PubMedCrossRef
5.
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. p. 1–76.
6.
7.
CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2017 update: a clinical practice guideline. [Internet]. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2017 update: a clinical practice guideline. 2017. https://​stacks.​cdc.​gov/​view/​cdc/​53509
8.
9.
Parsons JT, Rendina HJ, Lassiter JM, Whitfield THF, Starks TJ, Grov C, et al. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States: the Motivational PrEP Cascade HHS Public Access. J Acquir Immune Defic Syndr. 2017;74(3):285–92.PubMedPubMedCentralCrossRef
10.
Pyra MN, Haberer JE, Hasen N, Reed J, Mugo NR, Baeten JM. Global implementation of PrEP for HIV prevention: setting expectations for impact. J Int AIDS Soc. 2019;22(8):1–7.CrossRef
11.
Staritsky LE, Van Aar F, Visser M, Op de Coul ELM, Heijne J, Götz HM, et al. Sexually Transmitted Infections in the Netherlands in 2019. RIVM report 2020–0052. 2020.
12.
Hoornenborg E, Krakower DS, Prins M, Mayer KH. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS. 2017;31(16):2179–91.PubMedCrossRef
13.
Reitsema M, van Hoek AJ, van der Loeff MS, Hoornenborg E, van Sighem A, Wallinga J, et al. Preexposure prophylaxis for men who have sex with men in the Netherlands. AIDS. 2020;34(4):621–30.PubMedCrossRef
14.
Blumenthal J, Jain S, Mulvihill E, Sun S, Hanashiro M, Ellorin E, et al. Perceived versus calculated HIV risk: implications for pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr. 2019;80(2):e23–9.PubMedPubMedCentralCrossRef
15.
Golub SA, Fikslin RA, Goldberg MH, Peña SM, Radix A. Predictors of PrEP uptake among patients with equivalent access. AIDS Behav. 2019;23(7):1917–24.PubMedPubMedCentralCrossRef
16.
Dubov A, Altice FL, Fraenkel L. An information–motivation–behavioral skills model of PrEP uptake. AIDS Behav. 2018;22(11):3603–16.PubMedCrossRef
17.
Haire B. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence – a narrative review. HIV/AIDS Res Palliat Care. 2015;13(7):241.CrossRef
18.
Bourne A, Alba B, Garner A, Spiteri G, Pharris A, Noori T. Use of, and likelihood of using, HIV pre-exposure prophylaxis among men who have sex with men in Europe and Central Asia: Findings from a 2017 large geosocial networking application survey. Sex Transm Infect. 2019;95(3):187–92.PubMedCrossRef
19.
Eaton LA, Matthews DD, Bukowski LA, Friedman MR, Chandler CJ, Whitfield DL, et al. Elevated HIV prevalence and correlates of PrEP use among a community sample of black men who have sex with men. J Acquir Immune Defic Syndr. 2018;79(3):339–46.PubMedPubMedCentralCrossRef
20.
Holloway IW, Dougherty R, Gildner J, Beougher SC, Pulsipher C, Montoya JA, et al. Brief report: PrEP uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. J Acquir Immune Defic Syndr. 2017;74(1):15–20.PubMedPubMedCentralCrossRef
21.
Okafor CN, Gorbach PM, Ragsdale A, Quinn B, Shoptaw S. Correlates of preexposure prophylaxis (PrEP) use among men who have sex with men (MSM) in Los Angeles, California. J Urban Heal. 2017;94(5):710–5.CrossRef
22.
Shover CL, Javanbakht M, Shoptaw S, Bolan RK, Lee SJ, Parsons JT, et al. HIV preexposure prophylaxis initiation at a large community clinic: differences between eligibility, awareness, and uptake. Am J Public Heal. 2018;108(10):1408–17.CrossRef
23.
Kuhns LM, Hotton AL, Schneider J, Garofalo R, Fujimoto K. Use of pre-exposure prophylaxis (PrEP) in young men who have sex with men is associated with race, sexual risk behavior and peer network size. AIDS Behav. 2017;21(5):1376–82.PubMedPubMedCentralCrossRef
24.
Marcus JL, Hurley LB, Hare CB, Silverberg MJ, Volk JE. Disparities in uptake of HIV preexposure prophylaxis in a large integrated health care system. Am J Public Health. 2016;106(10):e2-3.PubMedPubMedCentralCrossRef
25.
Hannaford A, Lipshie-Williams M, Starrels JL, Arnsten JH, Rizzuto J, Cohen P, et al. The use of online posts to identify barriers to and facilitators of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men: a comparison to a systematic review of the peer-reviewed literature. AIDS Behav. 2018;22(4):1080–95.PubMedPubMedCentralCrossRef
26.
Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “Truvada Whores.” Am J Public Health. 2015;105(10):1960–4.PubMedPubMedCentralCrossRef
27.
Thomann M, Grosso A, Zapata R, Chiasson MA. ‘WTF is PrEP?’: attitudes towards pre-exposure prophylaxis among men who have sex with men and transgender women in New York City. Cult Health Sex. 2018;20(7):772–86.PubMedCrossRef
28.
Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Pat Care STDS. 2013;27(4):248–54.CrossRef
29.
Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22(11):3681–91.PubMedPubMedCentralCrossRef
30.
Arnold T, Brinkley-Rubinstein L, Chan PA, Perez-Brumer A, Bologna ES, Beauchamps L, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12(2):10.CrossRef
31.
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31(5):545–53.PubMedCrossRef
32.
Bauermeister J, Meanley S, Pingel E, Soler J, Harper G. PrEP awareness and perceived barriers among single young men who have sex with men. Curr HIV Res. 2014;11(7):520–7.CrossRef
33.
Goparaju L, Praschan NC, Jeanpiere LW, Experton LS, Young MA, Kassaye S. Stigma, partners, providers and costs: potential barriers to PrEP uptake among US women. J AIDS Clin Res. 2017;08:09.CrossRef
34.
Rice WS, Stringer KL, Sohail M, Crockett KB, Atkins GC, Kudroff K, et al. Accessing pre-exposure prophylaxis (PrEP): perceptions of current and potential PrEP users in Birmingham, Alabama. AIDS Behav. 2019;23(11):2966–79.PubMedPubMedCentralCrossRef
35.
Pérez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of prep uptake among racially/ethnically diverse young men who have sex with men: the p18 study. AIDS Educ Prev. 2015;27(2):112–25.PubMedPubMedCentralCrossRef
36.
Kubicek K, Arauz-Cuadra C, Kipke MD. Attitudes and perceptions of biomedical HIV prevention methods: voices from young men who have sex with men. Arch Sex Behav. 2015;44(2):487–97.PubMedPubMedCentralCrossRef
37.
Schwartz J, Grimm J. PrEP on Twitter: information, barriers, and stigma. Health Commun. 2017;32(4):509–16.PubMedCrossRef
38.
Hayes R, Schmidt AJ, Pharris A, Azad Y, Brown AE, Weatherburn P, et al. Estimating the ‘PrEP Gap’: how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Eurosurveillance. 2019;24(41):1–7.CrossRef
39.
40.
Patel RR, Mena L, Nunn A, McBride T, Harrison LC, Oldenburg CE, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE. 2017;12(5):1–7.CrossRef
41.
42.
43.
44.
Hojilla JC, Koester KA, Cohen SE, Buchbinder S, Ladzekpo D, Matheson T, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav. 2016;20(7):1461–9.PubMedCentralCrossRef
45.
Elsesser SA, Oldenburg CE, Biello KB, Mimiaga MJ, Safren SA, Egan JE, et al. Seasons of risk: anticipated behavior on vacation and interest in episodic antiretroviral pre-exposure prophylaxis (PrEP) among a large national sample of US men who have sex with men (MSM). Aids Behav. 2016;20(7):1400–7.PubMedPubMedCentralCrossRef
46.
Underhill K, Guthrie KM, Colleran C, Calabrese SK, Operario D, Mayer KH. Temporal fluctuations in behavior, perceived HIV risk, and willingness to use pre-exposure prophylaxis (PrEP). Arch Sex Behav. 2018;47(7):2109–21.PubMedPubMedCentralCrossRef
47.
Kuo C, Giovenco D, DeAtley T, Hoare J, Underhill K, Atujuna M, et al. Recreational use of HIV antiretroviral medication and implications for HIV pre-exposure prophylaxis and treatment. AIDS Behav. 2020;24:2650–5.PubMedCrossRef
48.
Ai C, Norton EC. Interaction terms in logit and probit models. Econ Lett. 2003;80(1):123–9.CrossRef
49.
Hayes AF, Matthes J. Computational procedures for probing interactions in OLS and logistic regression: SPSS and SAS implementations. Behav Res Methods. 2009;41(3):924–36.PubMedCrossRef
50.
Blashill AJ, Brady JP, Rooney BM, Rodriguez-Diaz CE, Horvath KJ, Blumenthal J, et al. Syndemics and the PrEP cascade: results from a sample of young Latino men who have sex with men. Arch Sex Behav. 2020;49(1):125–35.PubMedCrossRef
51.
Rolle C-P, Rosenberg ES, Siegler AJ, Sanchez TH, Luisi N, Weiss K, et al. Challenges in translating PrEP interest into uptake in an observational study of young black MSM. J AIDS J Acquir Immune Defic Syndr. 2017;76(3):250–8.CrossRef
52.
53.
54.
55.
Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019;6(11):e788–99.PubMedCrossRef
56.
Metadata
Title
Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP
Authors
Mart van Dijk
John B. F. de Wit
Thomas E. Guadamuz
Joel E. Martinez
Kai J. Jonas
Publication date
01-08-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03200-4

Other articles of this Issue 8/2021

AIDS and Behavior 8/2021 Go to the issue

Commentary

“The Main Concern is HIV, Everything Else is Fixable”: Indifference Toward Sexually Transmitted Infections in the Era of Biomedical HIV Prevention

Original Paper

Mental Health, Coping, and Social Support Among People Living with HIV in the Americas: A Comparative Study Between Argentina and the USA During the SARS-CoV-2 Pandemic

Original Paper

African American/Black and Latino Adults with Detectable HIV Viral Load Evidence Substantial Risk for Polysubstance Substance Use and Co-occurring Problems: A Latent Class Analysis

Original Paper

Using Incentives and Nudging to Improve Non-Targeted HIV Testing in Ecuador: A Randomized Trial

Original Paper

“We’ve Got Our Own Beliefs, Attitudes, Myths”: A Mixed Methods Assessment of Rural South African Health Care Workers' Knowledge of and Attitudes Towards PrEP Implementation

Original Paper

Predictors of Event-Driven Regimen Choice in Current PrEP Users and Sexual Behavior Characteristics of MSM Receiving Sexual Health Services in New York City
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits